De novo donor-specific HLA antibodies: Biomarkers of pancreas transplant failure

American Journal of Transplantation

Volumn 14, Issue 7, 2014, Pages 1664-1671

  Mittal, S ^a,b,c   Page, S L ^d   Friend, P J ^a,b   Sharples, E J ^a,e   Fuggle, S V ^a,b  

^a Oxford Transplant Centre   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^d OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Antibodies; pancreas transplant; risk factors; survival; transplant outcome; type 1 diabetes

Indexed keywords

BIOLOGICAL MARKER; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; METHYLPREDNISOLONE; ALLOANTIBODY; HLA ANTIGEN;

ADULT; ARTICLE; BRAIN DEATH; CLINICAL STUDY; COLD ISCHEMIA; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HIGH RISK POPULATION; HUMAN; IMMUNOTHERAPY; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY PANCREAS TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; OUTCOME ASSESSMENT; PANCREAS TRANSPLANTATION; PANCREATITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOSIS; BLOOD; CLINICAL TRIAL; COMPLICATION; DONOR; FOLLOW UP; GRAFT REJECTION; IMMUNOLOGY; PANCREATIC DISEASES; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RISK FACTOR;

ADULT; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; ISOANTIBODIES; MALE; PANCREAS TRANSPLANTATION; PANCREATIC DISEASES; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TISSUE DONORS;

EID: 84902987612     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12750     Document Type: Article

References (30)

1. Kandaswamy R, Stock PG, Skeans MA, et al. OPTN/SRTR 2011 annual data report: Pancreas. Am J Transplant 2013; 13 (Suppl 1): 47-72.
2. Kimball PM, Baker MA, Wagner MB, King A., Surveillance of alloantibodies after transplantation identifies the risk of chronic rejection. Kidney Int 2011; 79: 1131-1137.
3. Mao Q, Terasaki PI, Cai J, et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007; 7: 864-871.
4. Tait BD, Susal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95: 19-47.
5. Zito A, Schena A, Grandaliano G, Gesualdo L, Schena FP., Increasing relevance of donor-specific antibodies in antibody-mediated rejection. J Nephrol 2013; 26: 237-242.
6. Everly MJ, Rebellato LM, Haisch CE, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 2013; 95: 410-417.
7. Wiebe C, Nickerson P., Posttransplant monitoring of de novo human leukocyte antigen donor-specific antibodies in kidney transplantation. Curr Opin Organ Transplant 2013; 18: 470-477.
8. Caro-Oleas JL, Gonzalez-Escribano MF, Gentil-Govantes MA, et al. Influence of donor specific HLA antibodies detected by Luminex in kidney graft survival: A multivariate analysis. Human Immunol 2013; 74: 545-549.
9. Mohan S, Palanisamy A, Tsapepas D, et al. Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol 2012; 23: 2061-2071.
10. Smith JD, Banner NR, Hamour IM, et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant 2011; 11: 312-319.
11. Ho EK, Vlad G, Vasilescu ER, et al. Pre- and posttransplantation allosensitization in heart allograft recipients: Major impact of de novo alloantibody production on allograft survival. Human Immunol 2011; 72: 5-10.
12. Snyder LD, Wang Z, Chen DF, et al. Implications for human leukocyte antigen antibodies after lung transplantation: A 10-year experience in 441 patients. Chest 2013; 144: 226-233.
13. Campbell P., Clinical relevance of human leukocyte antigen antibodies in liver, heart, lung and intestine transplantation. Curr Opin Organ Transplant 2013; 18: 463-469.
14. O'Leary JG, Klintmalm GB., Impact of donor-specific antibodies on results of liver transplantation. Curr Opin Organ Transplant 2013; 18: 279-284.
15. Kaneku H, O'Leary JG, Banuelos N, et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant 2013; 13: 1541-1548.
16. Cantarovich D, De Amicis S, Akl A, et al. Posttransplant donor-specific anti-HLA antibodies negatively impact pancreas transplantation outcome. Am J Transplant 2011; 11: 2737-2746.
17. Mujtaba MA, Fridell JA, Higgins N, et al. Early findings of prospective anti-HLA donor specific antibodies monitoring study in pancreas transplantation: Indiana University Health Experience. Clin Transplant 2012; 26: E492-E499.
18. Bunce M, O'Neill CM, Barnardo MC, et al. Phototyping: Comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 1995; 46: 355-367.
19. Bryan CF, Martinez J, Muruve N, et al. IgM antibodies identified by a DTT-ameliorated positive crossmatch do not influence renal graft outcome but the strength of the IgM lymphocytotoxicity is associated with DR phenotype. Clin Transplant 2001; 15: 28-35.
20. Cooper JE, Gralla J, Chan L, Wiseman AC., Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts. Clin Transplant 2011; 359-364.
21. DeVos JM, Patel SJ, Burns KM, et al. De novo donor specific antibodies and patient outcomes in renal transplantation. Clin Transplant 2011; 351-358.
22. Vaziri ND, Pahl MV, Crum A, Norris K., Effect of uremia on structure and function of immune system. J Ren Nutr 2012; 22: 149-156.
23. de Kort H, Roufosse C, Bajema IM, Drachenberg CB., Pancreas transplantation, antibodies and rejection: Where do we stand ? Curr Opin Organ Transplant 2013; 18: 337-344.
24. Troxell ML, Koslin DB, Norman D, Rayhill S, Mittalhenkle A., Pancreas allograft rejection: Analysis of concurrent renal allograft biopsies and posttherapy follow-up biopsies. Transplantation 2010; 90: 75-84.
25. Cooper JE, Gralla J, Cagle L, Goldberg R, Chan L, Wiseman AC., Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation 2011; 91: 1103-1109.
26. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013; 369: 1215-1226.
27. Drachenberg CB, Torrealba JR, Nankivell BJ, et al. Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts-updated Banff grading schema. Am J Transplant 2011; 11: 1792-1802.
28. de Kort H, Munivenkatappa RB, Berger SP, et al. Pancreas allograft biopsies with positive c4d staining and anti-donor antibodies related to worse outcome for patients. Am J Transplant 2010; 10: 1660-1667.
29. Rangel EB, Malheiros DM, de Castro MC, et al. Antibody-mediated rejection (AMR) after pancreas and pancreas-kidney transplantation. Transplant Int 2010; 23: 602-610.
30. Kimelman M, Brandacher G., Trends in immunosuppression after pancreas transplantation: What is in the pipeline ? Curr Opin Organ Transplant 2013; 18: 76-82.